Chong-Xian Pan, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 32 | 2022 | 2184 | 4.600 |
Why?
|
| DNA Adducts | 6 | 2017 | 95 | 1.490 |
Why?
|
| Photochemotherapy | 5 | 2022 | 828 | 1.280 |
Why?
|
| Carboplatin | 7 | 2017 | 789 | 1.220 |
Why?
|
| Daunorubicin | 4 | 2019 | 157 | 1.080 |
Why?
|
| Carcinoma, Transitional Cell | 8 | 2022 | 790 | 0.960 |
Why?
|
| Peptides, Cyclic | 4 | 2016 | 390 | 0.840 |
Why?
|
| Micelles | 5 | 2019 | 190 | 0.770 |
Why?
|
| Deoxycytidine | 7 | 2020 | 886 | 0.690 |
Why?
|
| Drug Delivery Systems | 6 | 2016 | 2210 | 0.690 |
Why?
|
| Nanoparticles | 7 | 2019 | 1966 | 0.660 |
Why?
|
| Cell Line, Tumor | 24 | 2022 | 17088 | 0.660 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 204 | 0.650 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2014 | 678 | 0.640 |
Why?
|
| Paclitaxel | 4 | 2016 | 1727 | 0.620 |
Why?
|
| Porphyrins | 2 | 2018 | 352 | 0.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 11872 | 0.580 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2021 | 3607 | 0.570 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 125 | 0.540 |
Why?
|
| Antineoplastic Agents | 11 | 2019 | 13643 | 0.520 |
Why?
|
| Cisplatin | 4 | 2017 | 1655 | 0.510 |
Why?
|
| Urinary Bladder | 3 | 2022 | 1155 | 0.510 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 596 | 0.490 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2010 | 136 | 0.490 |
Why?
|
| Immunoconjugates | 1 | 2022 | 976 | 0.460 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 904 | 0.450 |
Why?
|
| Immunotherapy | 5 | 2022 | 4747 | 0.450 |
Why?
|
| Pyridazines | 1 | 2015 | 199 | 0.440 |
Why?
|
| Lectins, C-Type | 2 | 2019 | 592 | 0.430 |
Why?
|
| DNA Repair | 5 | 2016 | 2050 | 0.430 |
Why?
|
| Drug Carriers | 3 | 2018 | 702 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 5329 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 1351 | 0.380 |
Why?
|
| Microscopy, Fluorescence | 2 | 2016 | 2629 | 0.370 |
Why?
|
| Peptides | 3 | 2011 | 4344 | 0.350 |
Why?
|
| Dog Diseases | 1 | 2011 | 143 | 0.340 |
Why?
|
| Quinolines | 1 | 2015 | 769 | 0.340 |
Why?
|
| Piperazines | 1 | 2020 | 2547 | 0.330 |
Why?
|
| Drug Synergism | 4 | 2021 | 1756 | 0.330 |
Why?
|
| Imidazoles | 1 | 2015 | 1168 | 0.320 |
Why?
|
| Quinazolines | 1 | 2015 | 1367 | 0.310 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 1491 | 0.300 |
Why?
|
| Pyridines | 1 | 2020 | 2888 | 0.300 |
Why?
|
| Cell Survival | 7 | 2021 | 5748 | 0.300 |
Why?
|
| Photosensitizing Agents | 3 | 2018 | 627 | 0.300 |
Why?
|
| Cell Proliferation | 6 | 2021 | 10445 | 0.290 |
Why?
|
| Carcinoma, Small Cell | 2 | 2007 | 419 | 0.290 |
Why?
|
| Mice | 19 | 2022 | 81889 | 0.280 |
Why?
|
| Phototherapy | 2 | 2022 | 368 | 0.270 |
Why?
|
| Animals | 26 | 2022 | 168930 | 0.270 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 18330 | 0.270 |
Why?
|
| Oligopeptides | 2 | 2011 | 1195 | 0.260 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2004 | 80 | 0.230 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 1927 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2019 | 3636 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 6104 | 0.200 |
Why?
|
| Cell Cycle | 1 | 2010 | 2926 | 0.200 |
Why?
|
| Growth Substances | 1 | 2004 | 759 | 0.190 |
Why?
|
| Nanomedicine | 2 | 2015 | 289 | 0.190 |
Why?
|
| Gene Amplification | 2 | 2021 | 1088 | 0.190 |
Why?
|
| Administration, Intravesical | 1 | 2021 | 88 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2021 | 205 | 0.180 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 8540 | 0.180 |
Why?
|
| Cystectomy | 2 | 2021 | 603 | 0.180 |
Why?
|
| Neoplasms | 6 | 2022 | 22350 | 0.180 |
Why?
|
| Tissue Distribution | 3 | 2017 | 2275 | 0.170 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 2012 | 0.160 |
Why?
|
| Mice, Nude | 3 | 2018 | 3616 | 0.160 |
Why?
|
| Chlorophyll | 1 | 2018 | 30 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 635 | 0.160 |
Why?
|
| Humans | 47 | 2022 | 766766 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 3609 | 0.150 |
Why?
|
| Apoptosis | 4 | 2021 | 9513 | 0.150 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 476 | 0.150 |
Why?
|
| Benzoquinones | 1 | 2018 | 198 | 0.140 |
Why?
|
| Erythrocyte Membrane | 1 | 2018 | 438 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2020 | 352 | 0.140 |
Why?
|
| Dogs | 2 | 2012 | 3834 | 0.130 |
Why?
|
| Membrane Proteins | 2 | 2021 | 7868 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 562 | 0.130 |
Why?
|
| Lactams, Macrocyclic | 1 | 2018 | 319 | 0.130 |
Why?
|
| Receptors, Androgen | 2 | 2021 | 1089 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 520 | 0.130 |
Why?
|
| Indazoles | 1 | 2017 | 306 | 0.120 |
Why?
|
| Taxoids | 2 | 2016 | 665 | 0.120 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 789 | 0.120 |
Why?
|
| Ligands | 3 | 2011 | 3275 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 422 | 0.120 |
Why?
|
| Receptor, EphB2 | 1 | 2014 | 31 | 0.120 |
Why?
|
| Receptor, EphB4 | 1 | 2014 | 39 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 5690 | 0.120 |
Why?
|
| Mass Spectrometry | 4 | 2017 | 2198 | 0.120 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 406 | 0.110 |
Why?
|
| Hydrolases | 1 | 2015 | 146 | 0.110 |
Why?
|
| Dendrimers | 1 | 2014 | 72 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 1042 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2022 | 1594 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 3601 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 273 | 0.100 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 1189 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2011 | 464 | 0.100 |
Why?
|
| Glutathione | 2 | 2016 | 589 | 0.100 |
Why?
|
| Doxorubicin | 2 | 2016 | 2229 | 0.100 |
Why?
|
| Microfluidics | 1 | 2017 | 650 | 0.100 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 2391 | 0.100 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 312 | 0.100 |
Why?
|
| Peptide Library | 2 | 2010 | 351 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 1560 | 0.100 |
Why?
|
| Mice, SCID | 2 | 2018 | 2628 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 22352 | 0.090 |
Why?
|
| Arginine | 1 | 2015 | 932 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2022 | 23619 | 0.090 |
Why?
|
| Caspases | 1 | 2014 | 881 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2018 | 822 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2019 | 8106 | 0.090 |
Why?
|
| Carbocyanines | 1 | 2010 | 177 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 895 | 0.090 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 9547 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2597 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 13411 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 6222 | 0.080 |
Why?
|
| Nanotechnology | 1 | 2015 | 702 | 0.080 |
Why?
|
| Binding, Competitive | 1 | 2010 | 1141 | 0.080 |
Why?
|
| Jurkat Cells | 1 | 2010 | 740 | 0.080 |
Why?
|
| Protein Binding | 2 | 2011 | 9320 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 1331 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2823 | 0.080 |
Why?
|
| Female | 20 | 2022 | 396520 | 0.080 |
Why?
|
| Urothelium | 2 | 2014 | 275 | 0.070 |
Why?
|
| Prostatic Neoplasms | 3 | 2007 | 11094 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2017 | 1982 | 0.070 |
Why?
|
| Keratin-20 | 1 | 2006 | 31 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 6359 | 0.070 |
Why?
|
| Phosphorylcholine | 1 | 2007 | 152 | 0.070 |
Why?
|
| Cytokines | 1 | 2022 | 7438 | 0.070 |
Why?
|
| Keratin-7 | 1 | 2006 | 55 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 4853 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8621 | 0.070 |
Why?
|
| Isoflavones | 1 | 2007 | 139 | 0.070 |
Why?
|
| Male | 17 | 2022 | 364142 | 0.070 |
Why?
|
| Disulfides | 2 | 2019 | 462 | 0.060 |
Why?
|
| Hematuria | 1 | 2006 | 232 | 0.060 |
Why?
|
| DNA Damage | 2 | 2016 | 2467 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 1227 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 9611 | 0.060 |
Why?
|
| Exonucleases | 1 | 2004 | 42 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 11218 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4652 | 0.060 |
Why?
|
| Disease Progression | 1 | 2021 | 13640 | 0.060 |
Why?
|
| Papilloma | 1 | 2004 | 143 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 1838 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2022 | 12150 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9404 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2004 | 663 | 0.050 |
Why?
|
| Mutation | 4 | 2022 | 30213 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 1787 | 0.050 |
Why?
|
| Myocardium | 1 | 2014 | 4765 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2006 | 1776 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5890 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 2901 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 65273 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2021 | 2168 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5387 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 525 | 0.040 |
Why?
|
| Survival Rate | 2 | 2016 | 12825 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3552 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 10745 | 0.040 |
Why?
|
| Rats | 1 | 2014 | 23717 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2006 | 2572 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 1670 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 1657 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2007 | 11061 | 0.030 |
Why?
|
| Macrophages | 2 | 2022 | 5783 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2019 | 689 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2017 | 544 | 0.030 |
Why?
|
| Prostate | 1 | 2004 | 1757 | 0.030 |
Why?
|
| Platinum | 1 | 2016 | 219 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2020 | 1527 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1900 | 0.030 |
Why?
|
| Vinblastine | 1 | 2016 | 482 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1762 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 21162 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2881 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 616 | 0.030 |
Why?
|
| Light | 1 | 2018 | 1358 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 13485 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 1638 | 0.020 |
Why?
|
| California | 1 | 2016 | 1435 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1504 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2020 | 2493 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 1646 | 0.020 |
Why?
|
| Aged | 7 | 2017 | 171343 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2017 | 1592 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 3640 | 0.020 |
Why?
|
| Biological Transport | 1 | 2016 | 2083 | 0.020 |
Why?
|
| Organoids | 1 | 2017 | 740 | 0.020 |
Why?
|
| Middle Aged | 7 | 2017 | 223257 | 0.020 |
Why?
|
| Smoking | 1 | 2006 | 9077 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 2142 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3666 | 0.020 |
Why?
|
| Methotrexate | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 784 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 5795 | 0.020 |
Why?
|
| Color | 1 | 2008 | 297 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 59550 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 7609 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 428 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2017 | 3561 | 0.020 |
Why?
|
| Databases, Protein | 1 | 2007 | 390 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 10264 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2016 | 1880 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2057 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2008 | 1750 | 0.010 |
Why?
|
| Models, Biological | 1 | 2020 | 9461 | 0.010 |
Why?
|
| Microdissection | 1 | 2004 | 150 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 2631 | 0.010 |
Why?
|
| Exoribonucleases | 1 | 2004 | 88 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2017 | 8728 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2004 | 221 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 3053 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2004 | 784 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2017 | 18984 | 0.010 |
Why?
|
| Polysaccharides | 1 | 2007 | 1020 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 2510 | 0.010 |
Why?
|
| Lasers | 1 | 2004 | 951 | 0.010 |
Why?
|
| Registries | 1 | 2016 | 8351 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9525 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 5754 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 74881 | 0.010 |
Why?
|
| Age Factors | 1 | 2016 | 18397 | 0.010 |
Why?
|
| Adult | 5 | 2016 | 223307 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 9244 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 2456 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2008 | 3641 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 3425 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 8307 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 11920 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 29948 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39309 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6066 | 0.010 |
Why?
|
| United States | 1 | 2022 | 72951 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6550 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 59939 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 88904 | 0.000 |
Why?
|